Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 8000 of 8900 results

  1. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105

  2. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

  3. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

  4. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

  5. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

  6. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

  7. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

  8. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

  9. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

  10. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

  11. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

  12. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

  13. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

  14. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

  15. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

  16. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

  17. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

  18. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

  19. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    This guidance has been updated and replaced by NICE technology appraisal guidance 795.

  20. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

  21. Imanitib for chronic myeloid leukaemia (TA50)

    This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].

  22. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

  23. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

  24. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

  25. Ischaemic heart disease - coronary artery stents (TA4)

    This guidance has been replaced by NICE technology appraisal guidance 71